Morgan Stanley analyst Tejas Savant lowered the firm’s price target on Hologic (HOLX) to $65 from $77 and keeps an Equal Weight rating on the shares. Fiscal Q2 results were at the high end of guidance on Skeletal Health supply normalization, which offset Breast Health and Africa HIV testing headwinds, says the analyst, who views Hologic as “not quite out of the woods.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOLX:
- Hologic’s Hold Rating: Balancing Growth in Diagnostics with Challenges in Breast Health and Geopolitical Pressures
- Hologic’s Financial Outlook: Hold Rating Amid Revenue Decline and Tariff Challenges
- Hologic’s Earnings Call: Balancing Growth and Challenges
- Hologic price target lowered to $71 from $90 at Raymond James
- Hologic’s Mixed Q2 Performance and Revised Earnings Guidance Lead to Hold Rating